(D21) Addressing a GLP-1 Conundrum: Exposure in Conception, Pregnancy, and Postpartum

As the availability of novel weight loss and diabetes pharmacotherapy expands across the United States, diabetes care professionals are facing an unknown clinical landscape for individuals of childbearing age prescribed NuSH (nutrient-stimulated hormone) therapy. This presentation will quantify the increasing prescribing rates of NuSH therapy and outline appropriate management for individuals of childbearing age in various clinical scenarios including the use of emergency contraception. The bulk of this presentation will be spent evaluating existing literature for fetal and maternal safety in the setting of NuSH exposure antepartum. Lastly, this presentation will introduce clinical considerations for the CDCES advising their patients and clinical teams on the reintroduction of NuSH therapy postpartum.